Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) has been upgraded to a strong-buy rating by Wall Street Zen, moving from a previous "buy" rating.
• Wells Fargo raised its price target for KNSA from $30 to $42, while Jefferies increased it from $45 to $54, indicating strong analyst support for the stock.
• In the latest quarter, Kiniksa reported earnings per share of $0.23, exceeding expectations and achieving revenue of $156.8 million.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.

A number of other equities analysts also recently commented on KNSA. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Finally, Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Trading Down 1.7%

NASDAQ KNSA traded down $0.55 during trading on Friday, hitting $32.52. The company had a trading volume of 354,991 shares, compared to its average volume of 700,737. Kiniksa Pharmaceuticals International has a one year low of $17.82 and a one year high of $33.98. The company's fifty day moving average is $28.63 and its 200-day moving average is $24.31. The company has a market cap of $2.37 billion, a price-to-earnings ratio of 812.80 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider Ross Moat sold 27,594 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the sale, the insider directly owned 9,415 shares of the company's stock, valued at approximately $273,223.30. This represents a 74.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 18,900 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $28.72, for a total transaction of $542,808.00. Following the completion of the transaction, the chief operating officer directly owned 49,163 shares in the company, valued at $1,411,961.36. This represents a 27.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 296,862 shares of company stock valued at $8,537,453 in the last ninety days. Corporate insiders own 53.48% of the company's stock.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of the company. Braidwell LP raised its stake in shares of Kiniksa Pharmaceuticals International by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after purchasing an additional 557,934 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after purchasing an additional 651,700 shares in the last quarter. Millennium Management LLC raised its position in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after buying an additional 67,452 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in Kiniksa Pharmaceuticals International by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after acquiring an additional 54,361 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.